NeuraLight, a leader in precision biomarkers for neurological disorders, has announced that Prof. Thomas Südhof, a Nobel Prize-winning neuroscientist and a leading Alzheimer’s disease researcher, has joined its Scientific Advisory Board. This appointment follows the earlier announcement that Prof. Olivier Rascol, a highly regarded neurologist and co-creator of the widely used MDS-UPDRS scale for Parkinson’s disease progression, will serve as the head of the board. The addition of these world-class scientists brings together unmatched clinical and research expertise to strengthen NeuraLight’s validation-first approach, which has already produced eye-movement based progression measures demonstrating ten times greater sensitivity than the traditional MDS-UPDRS. Each member of the board will contribute to advancing NeuraLight’s clinical validation efforts, guiding pharmaceutical trial integration, and supporting the company’s efforts to scale precision progression measurement across multiple neurological disorders.

Health Technology Insights: Orsini and Dos Rx Partner to Support International Medical Travel Facilitation

Prof. Thomas Südhof, awarded the Nobel Prize in 2013 for his work on synaptic transmission, currently leads the Südhof Lab at Stanford University. As Scientific Co-founder at NeuraLight, he will oversee the scientific underpinnings of the company’s biomarker platform and help expand research in Alzheimer’s disease and other neurological conditions. Prof. Olivier Rascol brings over three decades of expertise in Parkinson’s disease research, including motor progression, disease modification, and clinical trial design. He is a professor of clinical pharmacology at Toulouse University Hospital and has conducted pioneering research on GLP-1 therapies for Parkinson’s disease. At NeuraLight, he will lead scientific strategy and guide the expansion of clinical applications for the platform. Prof. Alvin Roth, a Nobel Laureate in Economics in 2012, is a professor at Stanford University and contributes to NeuraLight by advising on market design, value-based partnerships, and ecosystem strategy.

Health Technology Insights: WindRose Health Investors Makes Strategic Investment in Stellus Rx

Edmund Ben-Ami, CEO and Co-founder of NeuraLight, stated that the appointment of these distinguished scientists is a major step in advancing the company’s clinical validation strategy and partnerships with pharmaceutical companies. He emphasized that the board’s expertise confirms NeuraLight’s potential to transform the measurement of disease progression in neurology.

NeuraLight has developed a tablet-based, ten-minute assessment that uses eye movement as a biomarker to detect disease changes that conventional methods often miss. The platform is currently being used in clinical partnerships worldwide, monitoring over 1,200 patients with Parkinson’s, ALS, multiple sclerosis, and Huntington’s disease, as well as in multiple pharmaceutical trials. Prof. Rascol noted that while clinical scales and imaging are useful, they can be noisy, expensive, and complex. He praised NeuraLight’s approach, stating that eye-movement biomarkers provide quantitative, objective measures that can detect subtle disease progression that traditional methods often overlook.

Supporting the board’s work are several key scientific advisors. Cristina Sampaio, Chief Medical Officer for the Cure Huntington’s Disease Initiative Foundation and Professor of Clinical Pharmacology and Therapeutics at the University of Lisbon, brings extensive expertise in movement disorders and clinical pharmacology. Prof. Fred Lublin, director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, is a renowned authority on MS treatment. Dr. Chris Goetz, co-creator of the MDS-UPDRS and professor at Rush University Medical Center, is a leading expert in movement disorder pharmacology and rating-scale development. Together, these advisors will support NeuraLight in refining its clinical strategy and expanding the impact of its precision biomarker platform across neurological diseases.

Health Technology Insights: GC Biopharma Ships First Doses of ‘BARYTHRAX inj.’ Anthrax Vaccine

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com